Urol. praxi. 2018;19(5):228-232 | DOI: 10.36290/uro.2018.093

Consequences of genitourinary malignancies therapy on cardiovascular system

prof. MUDr. Beata Mladosievičová, CSc., MUDr. Lucia Petríková, RNDr. Zuzana Poljak Valášková, Ph.D.
Oddelenie klinickej patofyziológie, Lekárska fakulta Univerzity Komenského, Bratislava

Cardiovascular toxicity induced by conventional anticancer drugs (anthracyclines and platinum compounds) has historically beena relevant issue of patients with genitourinary malignancies. In addition, targeted and androgen-deprivation therapies can alsoinduce cardiotoxicity in these patients. Immune checkpoint inhibitors are a novel class of effective antineoplastic drugs withcardiotoxicity used in patients with urogenital malignancies. Cardiotoxicity has been long underestimated in clinical practice,but during the last years significant number of patients with serious cardiovascular complications during or after completionof anticancer therapy have been reported. Here we describe cardiotoxicity of the selected prominent drugs used in the field ofurooncology which have received particular attention in recent years.

Keywords: cardiac toxicity, vascular toxicity, cisplatin, androgen-deprivation therapy, checkpoint inhibitors

Published: December 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mladosievičová B, Petríková L, Poljak Valášková Z. Consequences of genitourinary malignancies therapy on cardiovascular system. Urol. praxi. 2018;19(5):228-232. doi: 10.36290/uro.2018.093.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Mardiak J, a kol. Nádory genitourinárneho traktu. Univerzita Komenského v Bratislave; 2013; 138.
    2. Zamorano JL, Lancellotti P, Rodriguez, et al. ESC Committee for Practice Guidelines (CPG). 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart. J 2016; 37: 2768-2801. Go to original source... Go to PubMed...
    3. Vyskočil J, Petráková K, Jelínek P, Furdek M. Cardiovascular complications of cancers and anti-cancer therapy. Vnitr Lek. Spring. 2017; 63(3): 200-209. Go to original source... Go to PubMed...
    4. Carver JR, Desai CJ. Cardiovascular toxicity of antitumor drugs: dimension of the problem in adult settings. In: Minotti G. Cardiotoxicity of non-cardiovasculardrugs. Wiley; 2010: 127-199. Go to original source...
    5. Iliescu CA, Grines CL, Herrmann J, et al. SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiolog?a intervencionista). Catheter Cardiovasc Interv. 2016; 87(5): E202-E223. Go to original source... Go to PubMed...
    6. Mladosievičová B a kol. Kardioonkologie, 2. přepracované a doplněné vydání. Praha: Grada Publishing, a.s.; 2014: 208.
    7. Puzanov I, Diab A, Addallab K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity. J Immunother Cancer. 2017 Nov 21; 5(1): 95. Go to original source... Go to PubMed...
    8. Herrmann J, Yang EH, Iliescu CA, et al. Vascular Toxicities of Cancer Therapies: The Old and the New-An Evolving Avenue. Circulation. 2016 Mar 29; 133(13): 1272-1289. Go to original source... Go to PubMed...
    9. Gietema JA, Meinardi MT, Messerschmidt J, et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet. 2000; 355(9209): 1075-1076. Go to original source... Go to PubMed...
    10. Chovanec M, Abu Zaid M, Hanna N, et al. Long-term toxicity of cisplatin in germ-cell tumor survivors. Ann Oncol. 2017 Nov 1; 28(11): 2670-2679. Go to original source... Go to PubMed...
    11. Valentová M, Mladosievicová B. Coronary heart disease and hypertension as late effects of testicular cancer treatment-a minireview. Klin Onkol. 2011; 24(1): 18-22. Go to PubMed...
    12. Carneiro A, Sasse AD, Wagner AA, et al. Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis. World J Urol. 2015; 33: 1281-1289. Go to original source... Go to PubMed...
    13. Greiman AK, Keane TE. Approach to androgen deprivation in the prostate cancer patient with pre-existing cardiovascular disease. Curr Urol Rep. 2017; 18: 41. Go to original source... Go to PubMed...
    14. Poljak Z, Hulin I, Maruscakova L, Carter A, Mladosievicova B. Androgen deprivation therapy and cardiovascular complications. Bratisl Med J. 2016; 117: 557-561. Go to original source... Go to PubMed...
    15. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006; 24: 4448-4456. Go to original source... Go to PubMed...
    16. Scailteux LM, Vincendeau S, Balusson F, et al. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data. Eur J Cancer. 2017; 77: 99-108. Go to original source... Go to PubMed...
    17. O'Farrell S, Garmo H, Holmberg L, et al. Risk and timing of cardiovasculardisease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2015; 33(11): 1243-1251. Go to original source... Go to PubMed...
    18. Albertsen PC. Re: Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists. Eur J Cancer. 2017; 87: 203. Go to original source... Go to PubMed...
    19. Matoušková M, Hanuš M, Králová V. Léčba metstatického kastračne refrakterního karcinómu prostaty - abirateron acetát jako první volba. Urol. praxi. 2015; 16(4): 162-164.
    20. Sternberg CN, Castellano D, Daugaard G, et al. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. Lancet Oncol. 2014; 15(11): 1263-1268. Go to original source... Go to PubMed...
    21. Campora S, Campazzi E, Zanardi S, et al. Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer. Transl Oncol. 2016; 9(6): 600-605. Go to original source... Go to PubMed...
    22. Levine GN, D'Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin. 2010; 60: 194-201. Go to original source... Go to PubMed...
    23. Sauer R, Kiewe P, Desole M, Schuler M, et al. Lymphocytic myocarditis in a patient with metastatic clear cell renal cell carcinoma treated with Nivolumab. Pathologe. 2017; 38(6): 535-539. Go to original source... Go to PubMed...
    24. ##
    25. Lerner S, Davis I. Bladder cancer - moving into a new era of targeted treatment. Fast Facts, 3rd. edit., Oxford. 2018; 1-95. Go to original source...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.